Compare CTY & OBX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CTY | OBX |
|---|---|---|
| Founded | 2023 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 848.8M |
| IPO Year | 2026 | 2026 |
| Metric | CTY | OBX |
|---|---|---|
| Price | $17.55 | $13.10 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 5 |
| Target Price | $37.33 | ★ $38.67 |
| AVG Volume (30 Days) | 250.4K | ★ 531.9K |
| Earning Date | 12-01-2026 | 11-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $62.96 | N/A |
| Revenue Next Year | $7.47 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $15.81 | $9.60 |
| 52 Week High | $22.65 | $39.00 |
| Indicator | CTY | OBX |
|---|---|---|
| Relative Strength Index (RSI) | 41.04 | 48.71 |
| Support Level | $16.12 | $11.84 |
| Resistance Level | $21.98 | $15.87 |
| Average True Range (ATR) | 2.35 | 1.74 |
| MACD | -0.15 | 0.04 |
| Stochastic Oscillator | 25.44 | 59.12 |
City Therapeutics Inc is a clinical-stage biotechnology company developing the next generation of RNA interference (RNAi) therapeutics designed to silence the expression of disease-relevant proteins. Its current pipeline is focused on indications with unmet medical need, including thromboembolic diseases, Stargardt disease type 1 (Stargardt disease), and anemia of chronic disease.
Obsidian Therapeutics Inc is a clinical-stage biopharmaceutical company harnessing novel protein-regulation technology to develop engineered tumor infiltrating lymphocytes (TIL) cell therapies for the treatment of patients with solid tumors. The company's proprietary cytoDRiVE platform is versatile and allows it to leverage drug responsive domains to control protein function, with its initial focus on TIL cell therapies developed from this platform (cytoTILs). The company's flagship product candidate, OBX-115, is a novel, genetically engineered, autologous TIL cell therapy currently in a Phase 2 clinical trial for the treatment of melanoma and a Phase 1 clinical trial for the treatment of non-small cell lung cancer.